Amgen And Allergan Announce Positive Top-Line Results From Phase 1/ Phase 3 Study Of ABP 798, Biosimilar Candidate To Rituximab
Study Evaluated Pharmacokinetics, Efficacy and Safety of ABP 798 Compared to Rituximab in Patients With Moderate-to-Severe Rheumatoid Arthritis THOUSAND OAKS, Calif., Jan. 24, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc. (NYSE:AGN) today announced positive top-line results from a Phase 1/ Phase 3 study evaluating the pharmacokinetics, efficacy and safety of biosimilar candidate ABP 798, a biosimilar candidate to RITUXAN® (rituximab), compared to rituximab in patients with moderate-to-severe rheumatoid arthritis. The results demonstrate that the study met its primary endpoint of pharmacokinetic (PK) si...
Source: Amgen News Release - January 24, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

The MBDA Score Tracks Response to Rituximab Treatment in RA The MBDA Score Tracks Response to Rituximab Treatment in RA
Are changes in the MBDA score indicative of rituximab treatment efficacy in patients with rheumatoid arthritis?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 23, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

New treatment for adults with chronic lymphocytic leukaemia
NICE is recommending venetoclax with rituximab for adults with relapsed or refractory chronic lymphocytic leukaemia. Thousands of patients should benefit, NICE says. (Source: NHS Networks)
Source: NHS Networks - January 23, 2019 Category: UK Health Source Type: news

Maintenance Rituximab Post Bendamustine/Rituximab in FL
Is the continuation of maintenance rituximab beneficial post bendamustine plus rituximab treatment in FL Patients? (Source: CancerNetwork)
Source: CancerNetwork - January 22, 2019 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Drug May Delay MS Disability for Some
A new Swiss study found that people who have secondary progressive MS who took the drug rituximab reported less disabling symptoms over a 10-year period than those who didn't. People taking the drug also had a slower progression of MS symptoms. (Source: WebMD Health)
Source: WebMD Health - January 9, 2019 Category: Consumer Health News Source Type: news

Rituximab (Rituxan) May Delay MS Disability for Some
WEDNESDAY, Jan. 9, 2019 -- An immune system drug may help prevent or slow complications in a type of multiple sclerosis known as secondary progressive MS, a new study finds. The medication is called rituximab (Rituxan). It ' s used to treat a number... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 9, 2019 Category: General Medicine Source Type: news

Rituximab Beneficial in Secondary Progressive MS
MONDAY, Jan. 7, 2019 -- For patients with secondary progressive multiple sclerosis (SPMS), treatment with rituximab is associated with a significantly lower Expanded Disability Status Scale (EDSS) score and delayed progression, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 7, 2019 Category: Pharmaceuticals Source Type: news

Autoimmune Sequelae Following Rituximab Therapy Autoimmune Sequelae Following Rituximab Therapy
A new review provides insight into the mechanisms involved in the development of new autoimmune disease among patients receiving rituximab treatment.Journal of Clinical Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 26, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Lymphoma Still Top COD in Patients During Rituximab Era
Despite improved outcomes seen in the rituximab era, the leading cause of death in patients with follicular lymphoma during the first decade remains lymphoma. (Source: CancerNetwork)
Source: CancerNetwork - December 19, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Source Type: news

Another Rituximab Biosimilar Passes Lymphoma Test
(MedPage Today) -- Noninferior to EU-licensed agent in randomized trial (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 6, 2018 Category: Hematology Source Type: news

Truxima (Rituximab-abbs Injection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 6, 2018 Category: Drugs & Pharmacology Source Type: news

AbbVie Presents New Data from Phase 3 MURANO Trial of ...
- The data demonstrated that VENCLEXTA®/VENCLYXTO® in combination with rituximab (VenR) reduced the risk of disease progression or death compared to a standard of care, bendamustine plus rituximab (BR), after a median three-year follow-up[1] - Of the 130 patients who completed rituximab plus the 24-month fixed duration of venetoclax and remained off therapy for a median of 9.9 months, the estimated PFS rate at six and 12 months were 92 percent and 87 percent, respectively[1] -...This story is related to the following:Pharmaceuticals (Source: Industrial Newsroom - Health, Medical and Dental Supplies)
Source: Industrial Newsroom - Health, Medical and Dental Supplies - December 5, 2018 Category: Medical Devices Source Type: news

Ibrutinib and Rituximab for Untreated CLL:'Practice Changing'Ibrutinib and Rituximab for Untreated CLL:'Practice Changing '
The combination of ibrutinib and rituximab trumps the current gold standard chemoimmunotherapy of FCR in young, fit patients with untreated CLL in a large NCI trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 4, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New Phase 3 Study Findings Show IMBRUVICA ® (ibrutinib) Plus Rituximab Significantly Improved Survival Compared to Fludarabine, Cyclophosphamide, and Rituximab (FCR) in Previously Untreated Patients Aged 70 or Younger with Chronic Lymphocytic Leukemia
(Source: Johnson and Johnson)
Source: Johnson and Johnson - December 4, 2018 Category: Pharmaceuticals Source Type: news

Ibrutinib plus rituximab superior to standard treatment for some patients with chronic leukemia
Chronic lymphocytic leukemia is one of the most common types of leukemia in adults typically occurring during or after middle age and rarely occurring in individuals under the age of 40. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - December 4, 2018 Category: American Health Source Type: news